Study to assess the safety and Immunogenicity of monovalent mRNA NA vaccine in adult participants 18 years of age and older

Trial Identifier: FBP00012
Sponsor: Sanofi Pasteur, a Sanofi Company
Start Date: June 2022
Primary Completion Date: January 2024
Study Completion Date: January 2024
Condition: Healthy Volunteers; Influenza Immunisation

Available Languages

For questions about your Trial Results Summary, please see Sponsor contact section within your Trial Results Summary.

No documents have been posted yet.

Trial Locations

Country Location
United States, Alabama Huntsville, Alabama, United States, 35802
United States, Arizona Phoenix, Arizona, United States, 85020
United States, California San Diego, California, United States, 92108
United States, Florida Melbourne, Florida, United States, 32934-8172
United States, Illinois Peoria, Illinois, United States, 61614-4885
United States, Ohio Cincinnati, Ohio, United States, 45236